Side Effect Management
Researchers noted that while non-drug costs account for only 7% of CAR-T therapy-related expenses, these costs may range from $30,000 to $56,000.
It was unknown whether breast cancer treatment plays a causal role in the onset of diabetes.
A previous analysis showed that APBI had non-inferior efficacy.
The total morphine equivalents used were, however, not significantly different between arms.
The number of PCA attempts did not differ between treatment arms.
Patients with CLL may have both disease-associated and systemic treatment-associated immune dysfunction, leaving them vulnerable to infection.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.
Improvements in alopecia were, however, seen in 37 of 46 patients treated with topical minoxidil.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
Drug Info Database
More from Oncology Nurse Advisor
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Non-Drug Costs of CAR-T Cell Therapy May Exceed $50,000
- Information About Obese Patients Underreported in Randomized Clinical Trials
- Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenstrom Macroglobulinemia
- The Benefits of Adjuvant Immunotherapy in Melanoma
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR